Funding for this research was provided by:
National Institutes of Health (T32 - HL007854, K23- DK111847)
U.S. Department of Defense (PR-181960)
National Institute of Neurological Disorders and Stroke (5T32 - NS007153)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (U01- AR068043, R01 - AR050026)
National Institute of Diabetes and Digestive and Kidney Diseases (U01- DK116066, R01 - MD014161)
National Heart, Lung, and Blood Institute (R01 - HL152236, R03 - HL146881, K08-HL122526)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
Received: 29 April 2020
Accepted: 5 June 2020
First Online: 10 July 2020
: A. G. received payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation and from the Ben C. Martin Law Firm for work related to the Cook inferior vena cava filter litigation; received consulting fees from Edward Lifesciences; and holds equity in the healthcare telecardiology startup Heartbeat Health. B. B. reports being a consulting expert, on behalf of the plaintiff, for litigation related to a specific type of inferior vena cava filter. A. J. K. reports institutional funding to Columbia University and/or the Cardiovascular Research Foundation from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, Philips, and ReCor Medical. J. M. B. reports an honorarium for participation on a grants review panel for Gilead Biosciences. D. A. is founder, director, and chair of the advisory board of Forkhead Therapeutics. H. M. K. works under contract with the Centers for Medicare & Medicaid Services to support quality measurement programs; was a recipient of a research grant, through Yale University, from Medtronic and the US Food and Drug Administration to develop methods for post-market surveillance of medical devices; was a recipient of a research grant with Medtronic and is the recipient of a research grant from Johnson & Johnson, through Yale University, to support clinical trial data sharing; was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, from the Ben C. Martin Law Firm for work related to the Cook Celect IVC filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a participant or participant representative of the IBM Watson Health Life Sciences Board; is a member of the advisory board for Element Science, the advisory board for Facebook, and the physician advisory board for Aetna; and is the co-founder of HugoHealth (a personal health information platform) and co-founder of Refactor Health (an enterprise healthcare AI-augmented data enterprise). M. R. M. reports consulting relationships with Abbott, Medtronic, Janssen, Mesoblast, Portola, Bayer, NupulseCV, FineHeart, Leviticus, Roivant, and Triple Gene. D. W. L. is the chair of the scientific advisory board for Applied Therapeutics, licensor of Columbia University technology unrelated to COVID-19 or COVID-19-related therapies.
Free to read: This content has been made available to all.